San Sebastián – – October 19, 2026 -- Viralgen, the AAV gene therapy contract manufacturer owned by Bayer unit AskBio, has appointed Bayer executive Angela Ochoa Chico as chief executive effective January 1, 2027, replacing Jimmy Vanhove after four years in the role.

Vanhove moves to lead Bayer's U.S. pharmaceutical supply network expansion

Vanhove will lead the development and expansion of Bayer's U.S. Pharmaceutical Product Supply Network, based in New Albany, Ohio. He will join the Pharmaceuticals Division's Product Supply Leadership Team.

London and San Sebastián, Spain – September 12, 2026 -- EpilepsyGTx has partnered with AAV-focused CDMO Viralgen to manufacture EPY201, an investigational gene therapy targeting focal refractory epilepsy (FRE), a condition affecting an estimated 10 million patients worldwide, including 2 million across the US, UK and EU.